Intradialytic hypotension frequency is reduced by levocarnitine supplementation

Introduction: Intradialytic hypotension (IDH) is a frequent complication of hemodialysis. IDH causes intradialytic discomfort and subclinical ischemia, resulting in higher rate morbidity mortality. Levocarnitine (LC) administration has been suggested for the treatment IDH, but conflicting reports about its efficacy have published. We describe effect LC supplementation patients experiencing recurrent episodes, spite common strategies used to prevent it. Methods: Sixteen hemodialysis were studied. was defined as drop systolic blood pressure ≥20 mmHg, with or without symptoms, prompting an intervention by dialysis staff, such reducing/stopping ultrafiltration and/or fluid administration. Blood recorded 192 sessions, before supplementation. Thereafter (30 mg/kg dry weight) administered at beginning each hemodialysis, registering 384 treatments. The difference between predialysis minimum evaluated (∆SBP), after Cardiac ejection fraction also measured. Results: Predialysis postdialysis systolic, diastolic, mean arterial pressures did not differ Before supplementation, 36 episodes occurred (19%), while 29 during sessions (8%; χ2 = 16.03; p 0.0001). ∆SBP lower even though significant (p 0.22). Conclusion: frequency significantly reduced which can be helpful patients’ well-being reduction IDH-associated risks.